CONVERGE-01: Dosimetry, randomized dose optimization, dose escalation, and efficacy of ac-225 rosopatamab tetraxetan in participants with PSMA-positive castration-resistant prostate cancer.

177Lu-rosopatamab tetraxetan (TLX591) - Telix

Ac-225 rosopatamab tetraxetan (CONV01-α) - Convergent Therapeutics

https://meetings.asco.org/abstracts-presentations/243050/

Michael Morris; Ana Kiess; Luke Nordquist; Shilpa Gupta; Daniel George; Richard Messmann; Philip Kantoff; Jones Nauseef; Neil Bander; Emmanuel Antonarakis

Jan 7, 2025